Conatus Pharmaceutic (CNAT) 1.84 $CNAT Exalenz
Post# of 273257
Posted On: 09/04/2016 3:14:04 AM
Conatus Pharmaceutic (CNAT) 1.84 $CNAT
Exalenz Bioscience Announces Collaboration with Conatus Pharmaceuticals to Use BreathID® to Monitor Patients with Cirrhosis Associated with NASH
PR Newswire - Mon Aug 29, 7:00AM CDT
Exalenz Bioscience (TASE: EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) to use the BreathID® Methacetin Breath Test (MBT) to monitor patients in a planned Phase IIb clinical trial evaluating emricasan. Emricasan is an investigational treatment for patients with chronic liver disease, being developed by Conatus.
CNAT: 1.84 (-0.02)
Conatus (CNAT) Posts Narrower Q2 Loss, Emricasan in Focus
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 11:16AM CDT
Conatus Pharmaceuticals (CNAT) reported narrower-than-expected second-quarter 2016 loss of 30 cents per share.
FCSC: 0.89 (-0.01), ANIP: 59.86 (-1.56), CNAT: 1.84 (-0.02), ANIK: 47.89 (-0.05)
Conatus Pharmaceuticals Reports Second Quarter 2016 Financial Results and Program Updates
GlobeNewswire - Wed Aug 03, 3:16PM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and six months ended June 30, 2016, and provided updates on its clinical development programs.
CNAT: 1.84 (-0.02)
Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:30AM CDT
Can drug stocks Zoetis, Conatus and others pull a surprise when they report their Q2 results on Aug 3?
ZTS: 51.26 (+0.15), JNJ: 119.32 (+0.24), GILD: 76.89 (-0.53), GERN: 2.75 (+0.02), CNAT: 1.84 (-0.02), AERI: 19.60 (+0.39), EXEL: 11.54 (+0.19)
Medical Product Stocks Earnings Preview for Aug 3: BIO, CSII & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:35AM CDT
Medical has been a stand out performer so far in Q2.
MGNX: 29.64 (-0.41), INSY: 14.63 (+0.27), CSII: 24.69 (+0.24), BIO: 151.14 (+1.65), CNAT: 1.84 (-0.02)
Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:36PM CDT
Conatus (CNAT), which is set to report second-quarter 2016 results on Aug 3, posted in-line results last quarter. Will the stock pull a surprise this quarter?
BMRN: 95.73 (+0.54), CNAT: 1.84 (-0.02), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
BioMarin (BMRN) May Beat in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:04AM CDT
BioMarin (BMRN), which is scheduled to report second-quarter 2016 results on Aug 4, had delivered a positive earnings surprise of 58.82% last quarter.
BMRN: 95.73 (+0.54), CNAT: 1.84 (-0.02), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
Regeneron (REGN) Q2 Earnings: Can the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 10:58AM CDT
Regeneron Pharmaceuticals (REGN), which is set to release second-quarter 2016 results on Aug 4, had recorded an average negative earnings surprise of 0.06% last quarter.
CNAT: 1.84 (-0.02), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Conatus to Present at JMP Securities Life Sciences Conference
GlobeNewswire - Tue Jun 14, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its planned participation in the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, in New York. The company is scheduled to engage in a "fireside chat" with a JMP Securities analyst and expects to host meetings with invited institutional investors. The company will post a current company overview presentation in the Investors section of its website at www.conatuspharma.com.
CNAT: 1.84 (-0.02)
Conatus (CNAT) Posts In Line Q1 Loss , Focus on Emricasan
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:32AM CDT
Conatus Pharmaceuticals (CNAT) reported first-quarter 2016 loss of 35 cents per share, in line with the Zacks Consensus Estimate.
VTL: 6.15 (+0.27), ANIP: 59.86 (-1.56), CNAT: 1.84 (-0.02), RTRX: 16.10 (-0.25)
Conatus' (CNAT) Q1 Loss in Line with Expectation
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:30AM CDT
Conatus' first-quarter 2016 loss of 35 cents per share came in line with consensus estimates.
CNAT: 1.84 (-0.02)
Conatus reports 1Q loss
Automated Insights - Thu May 05, 6:40AM CDT
SAN DIEGO (AP) _ Conatus Pharmaceuticals Inc. (CNAT) on Thursday reported a loss of $7.3 million in its first quarter.
CNAT: 1.84 (-0.02)
Conatus Pharmaceuticals Reports First Quarter 2016 Financial Results and Program Updates
GlobeNewswire - Thu May 05, 6:00AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the first quarter ended March 31, 2016, and provided updates on its development programs. After the market close yesterday, the company announced top-line results from the second stage of its Phase 2 Liver Cirrhosis trial. A conference call and webcast are scheduled for 8:00 a.m. ET today, as detailed below, to discuss both the trial results and financial results.
CNAT: 1.84 (-0.02)
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 42.09 (-0.21), BIIB: 313.59 (+7.56), CNAT: 1.84 (-0.02), AMGN: 169.77 (-0.36), RPRX: 2.00 (unch), JNJ: 119.32 (+0.24), GILD: 76.89 (-0.53), GWPH: 82.73 (+0.45), GERN: 2.75 (+0.02), AVEO: 0.90 (-0.01), ICPT: 150.74 (+3.92), AGIO: 36.35 (-0.39), NVS: 79.38 (+1.11)
Conatus (CNAT): Can the Stock Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:57PM CDT
Conatus (CNAT) is scheduled to report first-quarter 2016 results on May 5, before market opens.
ZTS: 51.26 (+0.15), IPXL: 24.03 (+0.09), CNAT: 1.84 (-0.02), JAZZ: 120.84 (-2.47)
Conatus Pharmaceuticals to Report First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 28, 6:32AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the first quarter ended March 31, 2016, before the market opens on Thursday, May 5, 2016. Conatus will host a conference call and audio webcast at 8:00 a.m. Eastern Time on Thursday, May 5, 2016, to discuss the financial results and provide a corporate update.
CNAT: 1.84 (-0.02)
Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
GlobeNewswire - Mon Apr 18, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the delivery of a late breaker oral presentation at The International Liver Congress(TM) 2016, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain, April 13-17, 2016. The presentation (#LBO5) entitled, "Emricasan (IDN-6556) orally for three months in patients with cirrhosis and MELD scores 11-18 improves clinical parameters of cirrhosis in patients with baseline MELD score greater-than or equal to15," was delivered on Saturday, April 16, at 5:00 p.m. CET, by Catherine Frenette, M.D., Medical Director of Liver Transplantation at Scripps Clinic, La Jolla, CA, and a principal investigator in the company's multicenter Phase 2 Liver Cirrhosis clinical trial of emricasan. The presentation visuals are available in the Clinical Data section of the Conatus website at www.conatuspharma.com.
CNAT: 1.84 (-0.02)
Conatus Poster at EASL Meeting Today Addresses Safety of Caspase Inhibition in Cancer Treatment
GlobeNewswire - Fri Apr 15, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that a poster addressing results in both ex vivo cell culture and in vivo mouse models of hepatocellular carcinoma with IDN-7314, an orally active pan-caspase inhibitor, is being presented today at The International Liver Congress(TM) 2016, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain, April 13-17, 2016.
CNAT: 1.84 (-0.02)
Penny Stocks: Wednesday's List Of Trending Micro Cap And Small Cap Equities
ACCESSWIRE - Wed Apr 06, 11:25AM CDT
MIAMI, FL / ACCESSWIRE / April 6, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. TRTC, NETE, SFOR, and UNXL have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
VCRA: 16.27 (+0.32), CNAT: 1.84 (-0.02)
Conatus to Present at Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the 15 Annual Needham Healthcare Conference on Wednesday, April 13, 2016, at 9:20 a.m. ET, in New York. An audio webcast and copy of the presentation will be available in the Investors section of the company's website at www.conatuspharma.com.
CNAT: 1.84 (-0.02)
Exalenz Bioscience Announces Collaboration with Conatus Pharmaceuticals to Use BreathID® to Monitor Patients with Cirrhosis Associated with NASH
PR Newswire - Mon Aug 29, 7:00AM CDT
Exalenz Bioscience (TASE: EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) to use the BreathID® Methacetin Breath Test (MBT) to monitor patients in a planned Phase IIb clinical trial evaluating emricasan. Emricasan is an investigational treatment for patients with chronic liver disease, being developed by Conatus.
CNAT: 1.84 (-0.02)
Conatus (CNAT) Posts Narrower Q2 Loss, Emricasan in Focus
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 11:16AM CDT
Conatus Pharmaceuticals (CNAT) reported narrower-than-expected second-quarter 2016 loss of 30 cents per share.
FCSC: 0.89 (-0.01), ANIP: 59.86 (-1.56), CNAT: 1.84 (-0.02), ANIK: 47.89 (-0.05)
Conatus Pharmaceuticals Reports Second Quarter 2016 Financial Results and Program Updates
GlobeNewswire - Wed Aug 03, 3:16PM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and six months ended June 30, 2016, and provided updates on its clinical development programs.
CNAT: 1.84 (-0.02)
Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:30AM CDT
Can drug stocks Zoetis, Conatus and others pull a surprise when they report their Q2 results on Aug 3?
ZTS: 51.26 (+0.15), JNJ: 119.32 (+0.24), GILD: 76.89 (-0.53), GERN: 2.75 (+0.02), CNAT: 1.84 (-0.02), AERI: 19.60 (+0.39), EXEL: 11.54 (+0.19)
Medical Product Stocks Earnings Preview for Aug 3: BIO, CSII & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:35AM CDT
Medical has been a stand out performer so far in Q2.
MGNX: 29.64 (-0.41), INSY: 14.63 (+0.27), CSII: 24.69 (+0.24), BIO: 151.14 (+1.65), CNAT: 1.84 (-0.02)
Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:36PM CDT
Conatus (CNAT), which is set to report second-quarter 2016 results on Aug 3, posted in-line results last quarter. Will the stock pull a surprise this quarter?
BMRN: 95.73 (+0.54), CNAT: 1.84 (-0.02), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
BioMarin (BMRN) May Beat in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:04AM CDT
BioMarin (BMRN), which is scheduled to report second-quarter 2016 results on Aug 4, had delivered a positive earnings surprise of 58.82% last quarter.
BMRN: 95.73 (+0.54), CNAT: 1.84 (-0.02), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
Regeneron (REGN) Q2 Earnings: Can the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 10:58AM CDT
Regeneron Pharmaceuticals (REGN), which is set to release second-quarter 2016 results on Aug 4, had recorded an average negative earnings surprise of 0.06% last quarter.
CNAT: 1.84 (-0.02), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Conatus to Present at JMP Securities Life Sciences Conference
GlobeNewswire - Tue Jun 14, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its planned participation in the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, in New York. The company is scheduled to engage in a "fireside chat" with a JMP Securities analyst and expects to host meetings with invited institutional investors. The company will post a current company overview presentation in the Investors section of its website at www.conatuspharma.com.
CNAT: 1.84 (-0.02)
Conatus (CNAT) Posts In Line Q1 Loss , Focus on Emricasan
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:32AM CDT
Conatus Pharmaceuticals (CNAT) reported first-quarter 2016 loss of 35 cents per share, in line with the Zacks Consensus Estimate.
VTL: 6.15 (+0.27), ANIP: 59.86 (-1.56), CNAT: 1.84 (-0.02), RTRX: 16.10 (-0.25)
Conatus' (CNAT) Q1 Loss in Line with Expectation
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:30AM CDT
Conatus' first-quarter 2016 loss of 35 cents per share came in line with consensus estimates.
CNAT: 1.84 (-0.02)
Conatus reports 1Q loss
Automated Insights - Thu May 05, 6:40AM CDT
SAN DIEGO (AP) _ Conatus Pharmaceuticals Inc. (CNAT) on Thursday reported a loss of $7.3 million in its first quarter.
CNAT: 1.84 (-0.02)
Conatus Pharmaceuticals Reports First Quarter 2016 Financial Results and Program Updates
GlobeNewswire - Thu May 05, 6:00AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the first quarter ended March 31, 2016, and provided updates on its development programs. After the market close yesterday, the company announced top-line results from the second stage of its Phase 2 Liver Cirrhosis trial. A conference call and webcast are scheduled for 8:00 a.m. ET today, as detailed below, to discuss both the trial results and financial results.
CNAT: 1.84 (-0.02)
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 42.09 (-0.21), BIIB: 313.59 (+7.56), CNAT: 1.84 (-0.02), AMGN: 169.77 (-0.36), RPRX: 2.00 (unch), JNJ: 119.32 (+0.24), GILD: 76.89 (-0.53), GWPH: 82.73 (+0.45), GERN: 2.75 (+0.02), AVEO: 0.90 (-0.01), ICPT: 150.74 (+3.92), AGIO: 36.35 (-0.39), NVS: 79.38 (+1.11)
Conatus (CNAT): Can the Stock Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:57PM CDT
Conatus (CNAT) is scheduled to report first-quarter 2016 results on May 5, before market opens.
ZTS: 51.26 (+0.15), IPXL: 24.03 (+0.09), CNAT: 1.84 (-0.02), JAZZ: 120.84 (-2.47)
Conatus Pharmaceuticals to Report First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 28, 6:32AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the first quarter ended March 31, 2016, before the market opens on Thursday, May 5, 2016. Conatus will host a conference call and audio webcast at 8:00 a.m. Eastern Time on Thursday, May 5, 2016, to discuss the financial results and provide a corporate update.
CNAT: 1.84 (-0.02)
Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
GlobeNewswire - Mon Apr 18, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the delivery of a late breaker oral presentation at The International Liver Congress(TM) 2016, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain, April 13-17, 2016. The presentation (#LBO5) entitled, "Emricasan (IDN-6556) orally for three months in patients with cirrhosis and MELD scores 11-18 improves clinical parameters of cirrhosis in patients with baseline MELD score greater-than or equal to15," was delivered on Saturday, April 16, at 5:00 p.m. CET, by Catherine Frenette, M.D., Medical Director of Liver Transplantation at Scripps Clinic, La Jolla, CA, and a principal investigator in the company's multicenter Phase 2 Liver Cirrhosis clinical trial of emricasan. The presentation visuals are available in the Clinical Data section of the Conatus website at www.conatuspharma.com.
CNAT: 1.84 (-0.02)
Conatus Poster at EASL Meeting Today Addresses Safety of Caspase Inhibition in Cancer Treatment
GlobeNewswire - Fri Apr 15, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that a poster addressing results in both ex vivo cell culture and in vivo mouse models of hepatocellular carcinoma with IDN-7314, an orally active pan-caspase inhibitor, is being presented today at The International Liver Congress(TM) 2016, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain, April 13-17, 2016.
CNAT: 1.84 (-0.02)
Penny Stocks: Wednesday's List Of Trending Micro Cap And Small Cap Equities
ACCESSWIRE - Wed Apr 06, 11:25AM CDT
MIAMI, FL / ACCESSWIRE / April 6, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. TRTC, NETE, SFOR, and UNXL have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
VCRA: 16.27 (+0.32), CNAT: 1.84 (-0.02)
Conatus to Present at Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the 15 Annual Needham Healthcare Conference on Wednesday, April 13, 2016, at 9:20 a.m. ET, in New York. An audio webcast and copy of the presentation will be available in the Investors section of the company's website at www.conatuspharma.com.
CNAT: 1.84 (-0.02)
(0)
(0)Scroll down for more posts ▼